Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 November 2025 | Story Martinette Brits | Photo Supplied
Opus Cactus
Prof Maryna Boshoff from the Department of Sustainable Food Systems and Development, Lerato Mamabolo (UFS graduate, now employed at OPUS Cactus), and Sotirios Pilafidis, Head of Research and Development at OPUS Cactus, at the XI International Congress on Cacti as Food, Fodder and Other Uses, hosted by the FAO-ICARDA CactusNet in Tenerife, Canary Islands.

The University of the Free State (UFS) has formalised a collaboration with OPUS Cactus, a pioneering biotech company focused on sustainable cactus-based farming and biorefineries in semi-arid regions. This partnership builds on OPUS Cactus’ expansion at the historic Waterkloof Research Station near Bloemfontein and combines the UFS’ academic expertise with industry innovation to promote climate-smart agriculture and economic development.

OPUS Cactus, led by Joeri van den Bovenkamp-Hofman, CEO, and Sotirios Pilafidis, Head of Research and Development (R&D), specialises in transforming marginal, non-arable land into productive, resource-efficient ecosystems by cultivating the drought-tolerant Opuntia cactus. This versatile biomass supports renewable bioenergy, animal feed, food production, fermentation feedstock, and sustainable biomaterials, while contributing to carbon capture and climate mitigation efforts.

“Our mission is to unlock the full potential of Opuntia biomass for sustainable bioenergy, food, and biomaterials, advancing regenerative agriculture and climate action,” says Van den Bovenkamp-Hofman. OPUS Cactus operates dual hubs: its headquarters and R&D lab in Groningen, the Netherlands, and the flagship 1 000-hectare Waterkloof Research Centre in the Free State. The Waterkloof facility serves as a commercial farm, research platform, and demonstration site for regenerative farming techniques.

The UFS collaboration involves multiple departments, including Sustainable Food Systems and Development, Soil, Crop and Climate Sciences, and Microbiology and Biochemistry. Profs Maryna Boshoff and Carlien Pohl-Albertyn, alongside Dr Gesine Coetzer, provide academic leadership in the partnership.

Prof Boshoff explains, “This industry-academia collaboration aims to develop innovative projects utilising cactus-based products. It builds on decades of cactus research at the UFS, enabling the translation of scientific knowledge into real-world impact through scale-up and commercialisation.”

 

Bridging academic research and commercial innovation to promote climate-smart agriculture

At the core of the partnership is the Waterkloof Research Centre, home to 42 spineless Burbank cactus pear cultivars. The facility acts as a ‘living laboratory’, integrating empirical research with commercial-scale farming. “Waterkloof now offers students and researchers access to operational infrastructure that cannot be replicated in conventional academic settings,” says Prof Boshoff.

Continuing projects at Waterkloof include biogas production through an anaerobic digester, regenerative agriculture practices such as cover cropping and reduced tillage, advanced plant biotechnology to breed superior cultivars, fermentation research for alternative proteins, and the development of novel fermented foods and sustainable biomaterials.

The collaboration also plays a critical role in conserving Opuntia genetic diversity and evaluating cultivars across South Africa’s varied agro-ecological zones. “Research done by UFS and ARC scientists on cultivar selection and cultivation is applied and scaled up through OPUS Cactus’ commercial operations,” Prof Boshoff adds.

This partnership provides valuable hands-on experience and career pathways for postgraduate students and young researchers. “We offer internships and employment opportunities, with several recent UFS graduates already joining our R&D team,” says Pilafidis. “We actively seek motivated graduates passionate about sustainable agriculture and bioengineering.”

By converting semi-arid landscapes into productive, carbon-sequestering ecosystems, the UFS-OPUS Cactus collaboration exemplifies how scientific innovation, entrepreneurship, and environmental stewardship can drive climate resilience, food security, and sustainable economic growth.

“OPUS Cactus is a win for the environment, communities, and business alike,” concludes Van den Bovenkamp-Hofman.

News Archive

Stem cell research and human cloning: legal and ethical focal points
2004-07-29

   

(Summary of the inaugural lecture of Prof Hennie Oosthuizen, from the Department of Criminal and Medical Law at the Faculty of Law of the University of the Free State.)

 

In the light of stem cell research, research on embryo’s and human cloning it will be fatal for legal advisors and researchers in South Africa to ignore the benefits that new bio-medical development, through research, contain for this country.

Legal advisors across the world have various views on stem cell research and human cloning. In the USA there is no legislation that regulates stem cell research but a number of States adopted legislation that approves stem cell research. The British Parlement gave permission for research on embryonic stem cells, but determined that it must be monitored closely and the European Union is of the opinion that it will open a door for race purification and commercial exploitation of human beings.

In South Africa the Bill on National Health makes provision for therapeutical and non therapeutical research. It also makes provision for therapeutical embryonical stem cell research on fetuses, which is not older than 14 days, as well as for therapeutical cloning under certain circumstances subject to the approval of the Minister. The Bill prohibits reproductive cloning.

Research on human embrio’s is a very controversial issue, here and in the rest of the world.

Researchers believe that the use of stem cell therapy could help to side-step the rejection of newly transplanted organs and tissue and if a bank for stem cell could be built, the shortage of organs for transplants would become something of the past. Stem cells could also be used for healing of Alzheimer’s, Parkinson’s and spinal injuries.

Sources from which stem cells are obtained could also lead to further ethical issues. Stem cells are harvested from mature human cells and embryonic stem cells. Another source to be utilised is to take egg cells from the ovaries of aborted fetuses. This will be morally unacceptable for those against abortions. Linking a financial incentive to that could become more of a controversial issue because the woman’s decision to abort could be influenced. The ideal would be to rather use human fetus tissue from spontaneous abortions or extra-uterine pregnancies than induced abortions.

The potential to obtain stem cells from the blood of the umbilical cord, bone-marrow and fetus tissue and for these cells to arrange themselves is known for quite some time. Blood from the umbilical cord contains many stem cells, which is the origin of the body’s immune and blood system. It is beneficial to bank the blood of a newborn baby’s umbilical cord. Through stem cell transplants the baby or another family member’s life could be saved from future illnesses such as anemia, leukemia and metabolic storing disabilities as well as certain generic immuno disabilities.

The possibility to withdraw stem cells from human embrio’s and to grow them is more useable because it has more treatment possibilities.

With the birth of Dolly the sheep, communities strongly expressed their concern about the possibility that a new cloning technique such as the replacement of the core of a cell will be used in human reproduction. Embryonic splitting and core replacement are two well known techniques that are associated with the cloning process.

I differentiate between reproductive cloning – to create a cloned human embryo with the aim to bring about a pregnancy of a child that is identical to another individual – and therapeutically cloning – to create a cloned human embryo for research purposes and for healing human illnesses.

Worldwide people are debating whether to proceed with therapeutical cloning. There are people for and against it. The biggest ethical objection against therapeutical cloning is the termination of the development of a potential human being.

Children born from cloning will differ from each other. Factors such as the uterus environment and the environment in which the child is growing up will play a role. Cloning create unique children that will grow up to be unique individuals, just like me and you that will develop into a person, just like you and me. If we understand this scientific fact, most arguments against human cloning will disappear.

Infertility can be treated through in vitro conception. This process does not work for everyone. For some cloning is a revolutionary treatment method because it is the only method that does not require patients to produce sperm and egg cells. The same arguments that were used against in vitro conception in the past are now being used against cloning. It is years later and in vitro cloning is generally applied and accepted by society. I am of the opinion that the same will happen with regard to human cloning.

There is an argument that cloning must be prohibited because it is unsafe. Distorted ideas in this regard were proven wrong. Are these distorted ideas justified to question the safety of cloning and the cloning process you may ask. The answer, according to me, is a definite no. Human cloning does have many advantages. That includes assistance with infertility, prevention of Down Syndrome and recovery from leukemia.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept